CASE STUDIES OF CONTRACTS UNDERTAKEN BY DRUG DISCOVERY AND DEVELOPMENT CONSULTANTS
The 3D team has worked on a variety of contracts for a range of clients from investment fund managers to pharma companies and include the following as examples of the work undertaken:
Operational support for the management of a first in human Phase I study
Operational support of asset in Phase II clinical development
Preclinical support of GLP tox-ready project
Due diligence review of pre-clinical package and CMC sections of a potential in-licensing asset
Generation of a report and presentation to potential investors for repurposing of a clinical stage asset with the inclusion of business plan, timelines and budget to clinical milestones.
Project proposal, costing and follow on support for University TTOs.
Provision of mechanism of action rationale, current status and potential future development options to support additional indications of a novel CNS drug candidate.
Literature review of potential new indication of an existing asset with a novel mechanism of action.
Review of literature and proprietary data package for investment fund manager of early stage pre-clinical asset of a potential NewCo.
Whilst at Proximagen, the Directors of 3D Consultants were responsible for managing and leading a workforce of almost 50 scientists and support staff, a budget of ~£15M and programmes spanning from early discovery through to, and including, Phase 2.
During this time, the team worked on multiple discovery and preclinical stage programmes leading to several clinical candidates progressing into the clinic including a VAP-1 Inhibitor which, following a successful outcome in a Phase 2 PoC study, was out-licensed to a top five pharmaceutical company.
As the core management team, the Directors were key contributors to the scientific assessment of business development opportunities, due diligence and external presentations to potential partners both for in-licensing and out-licensing assets.
Previously, part of the team successfully founded Cambridge Biotechnology Ltd with the IP generated and team of scientists recruited subsequently leading to three acquisitions (by Biovitrum, Proximagen and Upsher-Smith).